石藥/復星醫藥/石四藥/中生逆市續挫4%-7%財政部稽查藥企會計信息真實性
國家財政部聯同醫保局成立工作組稽查77家藥企會計信息真實性。醫藥板塊今天普遍逆市續捱沽,尤其是藍籌中生製藥(01177.HK)及石藥(01093.HK)連跌第三天,前者續挫6.8%,報7.1元,逐步考驗100天線(7.03元);後者低見11.46元,創近五個月低,現造11.64元,續跌3.8%。
石四藥(02005.HK)最低見5.83元,創四個半月低,現造5.91元,續挫4.8%。
復星醫藥(02196.HK)連跌第六天,今早高開報20.9元欠承接,掉頭低見21.05元,創近五個月低,現造21.25元,續挫4.7%,成交增至381萬股。
聯儲局主席鮑威爾昨晚指,會適當採取行動回應貿易爭端潛在風險,市場憧憬聯儲局減息,美股昨晚全面高收急彈近2.1%-2.7%。不過,因應環球貿易緊張局勢再次激化等因素,世銀將全球今年經濟增長預測下調0.3個百分點至2.6%。日經香港5月季調後PMI由48.4,降至46.9,為2016年6月以來最低。恆指扭五連跌,今早跟隨外圍高開354點或1.3%報27,116,受制10天線(27,130),升幅逐步收窄,最低見26,875,現造26,893,僅彈131點或0.5%,成交額377億元
財新中國5月服務業PMI降至52.7三個月低,遜於市場預期54。上證及深成扭轉連日跌勢,今早高開0.7%及近1%,升至2,888及8,851行人止步,掉頭回落,前者見2,866,現造2,874,僅彈0.4%;後者曾倒跌低見8,729,現造8,758,僅彈0.1%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.